Imaging-calculated splenic volume is associated with response in melanoma patients treated with immunotherapy.

Autor:	Oliveira Taveira M; Fundação Antônio Prudente, São Paulo, 01509-001, Brazil.; Hospital Sírio-Libanês, Brasília, 70200-730, Brazil., de Barros E Silva MJ; A.C.Camargo Cancer Center, São Paulo, 01509-001, Brazil., Vieira Barbosa Pinto PN; Fundação Antônio Prudente, São Paulo, 01509-001, Brazil.; A.C.Camargo Cancer Center, São Paulo, 01509-001, Brazil.
Jazyk:	angličtina
Zdroj:	Immunotherapy [Immunotherapy] 2023 Apr; Vol. 15 (5), pp. 343-351. Date of Electronic Publication: 2023 Feb 27.
DOI:	10.2217/imt-2022-0222
Abstrakt:	Background: Predicting the roughly 50% of melanoma patients that will respond to immunotherapy is challenging. We tested if splenic volume could be a predictive biomarker. Methods: Splenic volume was measured by a semiautomated commercial software tool in pre- and post-treatment PET/CT, CT or MRI in 50 melanoma patients treated with immune checkpoint inhibitors. Results: Subjects with smaller spleens had better progression-free survival (median not achieved after 30.6 months of follow-up vs median 11.2 months; p = 0.0213) than their counterparts. A cut-off of <244 cm 3 yielded a sensitivity of 83% and specificity of 54% to identify responders. Conclusion: Measuring splenic volume on imaging scans is feasible. Smaller pretreatment spleen volume is associated with better responses to immune checkpoint inhibitors.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu